Двухфазный инсулин аспарт 30 плюс метформин: эффективная комбинация для лечения сахарного диабета 2 типа
https://doi.org/10.14341/2072-0351-6119
Аннотация
популяции отсутствовали существенные различия качества гликемического контроля при терапии БИАсп 30, БИАсп 30 в комбинации с метформином или глибенкламид в комбинации с метформином. Следовательно, комбинация инсулина с метформином обеспечивает удовлетворительный контроль гликемии и может использоваться в качестве способа его оптимизации у больных СД 2 типа.
Об авторах
М КвапилА Сватко
К Хилберг
Марина Владимировна Шестакова
Список литературы
1. U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-883.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
3. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiology 2000; 7: 625-631.
4. Cusi K, DeFronzo RA. Metformin: a review of its meta-bolic effects. Diabetes Rev 1998; 6: 89-131.
5. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
6. Jacobsen LV, Sњgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399-403.
7. Weyer C, Heinemann L, Heise T. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614.
8. McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a doubleblind cross-over study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530-539.
9. Bo ..hm B, Home P, Behrend C, Kamp N, Lindholm A. Premixed insulin aspart 30 versus premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.
10. White JR. Combination oral agent/Insulin therapy in patients with type II diabetes mellitus. Clin Diab 1997; 15: 102-112.
11. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002; 25: 1691-1698.
12. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using oncedaily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003; 17: 307-313.
13. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double- blind, placebo-controlled trial. Ann Int Med 1999; 131: 182-188.
14. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-2237.
15. The Danish Drug Catalogue. Pedersen C, ed. Danish Drug Information a/S. Elanders Publishing A/S, Oslo, Norway 2002, 676-677.
16. Data on file. Novo Nordisk 87/ANA/DCD/037/USA.
17. European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products, Points to Consider on Adjustment for Baseline Covariates, 2003, CPMP/EWP/2863/99. Available at: http://www.emea.eu.int/pdfs/human/ewp/286399en.pdf.
18. Rohlfing CL, Wiedmeyer H, Little RR et al. Defining the relationship between plasma glucose and HbA1c - Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278.
19. Wolffenbuttel BHR, Sels JJE, Rondasa GJWM et al. Prog-nostic factors for successful insulin therapy in subjects with type 2 diabetes. Netherlands J Med 1998; 54: 63-69.
20. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
21. Tong PC, Chow CC, Jorgensen LN, Cockram CS. The contribution of metformin to glycaemic control in patients with type 2 diabetes mellitus receiving combination therapy with insulin. Diabetes Res Clin Prac 2002; 57: 93-98.
22. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
23. Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications trial. Diabetes Care 1995; 18: 1451-1427.
24. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-286.
25. Heller S. Reducing complications with insulin analogues. Int J Obes 2002; 26 (Suppl. 3): S31-S36.
26. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 1998; 34: 181-188.
Рецензия
Для цитирования:
Квапил М., Сватко А., Хилберг К., Шестакова М.В. Двухфазный инсулин аспарт 30 плюс метформин: эффективная комбинация для лечения сахарного диабета 2 типа. Сахарный диабет. 2006;9(2):50-59. https://doi.org/10.14341/2072-0351-6119
For citation:
Kvapil M., Svatko A., Khilberg K., Shestakova M.V. Dvukhfaznyy insulin aspart 30 plyusmetformin: effektivnaya kombinatsiyadlya lecheniya sakharnogo diabeta 2 tipa. Diabetes mellitus. 2006;9(2):50-59. (In Russ.) https://doi.org/10.14341/2072-0351-6119

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).